AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX

Key Points

• AIGH Capital Management acquired 2.8 million Kyverna Therapeutics shares worth approximately $24.9 million, making KYTX its 10th-largest holding and representing about 4.6% of the company.
• Kyverna reported a quarterly loss of $0.63 per share, beating the $0.68 consensus loss estimate, but analysts still expect the clinical-stage biotech to remain unprofitable this year.
• Analyst sentiment is mixed: HC Wainwright maintained a Buy rating and $25 target, while other firms remain bearish. Kyverna’s development-stage status, regulatory dependence and high volatility remain significant risks.

AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 2,795,797 shares of the company's stock, valued at approximately $24,911,000. Kyverna Therapeutics makes up 1.6% of AIGH Capital Management LLC's investment portfolio, making the stock its 10th largest position. AIGH Capital Management LLC owned approximately 4.60% of Kyverna Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in KYTX. Public Employees Retirement System of Ohio bought a new stake in Kyverna Therapeutics during the third quarter valued at $28,000. Qube Research & Technologies Ltd bought a new position in Kyverna Therapeutics in the 2nd quarter worth about $43,000. Rhumbline Advisers increased its stake in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after acquiring an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Kyverna Therapeutics in the 3rd quarter valued at about $77,000. Finally, Bank of America Corp DE raised its holdings in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock valued at $81,000 after acquiring an additional 6,400 shares in the last quarter. Institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Stock Performance

NASDAQ:KYTX opened at $8.17 on Monday. The company has a market capitalization of $505.23 million, a price-to-earnings ratio of -2.78 and a beta of 1.93. The business has a 50 day moving average of $8.07 and a 200 day moving average of $8.43. The company has a debt-to-equity ratio of 0.15, a current ratio of 9.06 and a quick ratio of 9.06. Kyverna Therapeutics, Inc. has a 1-year low of $3.27 and a 1-year high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.05. On average, sell-side analysts predict that Kyverna Therapeutics, Inc. will post -2.7 earnings per share for the current fiscal year.

Kyverna Therapeutics News Summary

Here are the key news stories impacting Kyverna Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its estimates across multiple periods, including FY2026 EPS to a loss of $2.70 from $2.98 and FY2027 EPS to a loss of $2.79 from $3.01. The firm maintained a Buy rating and a $25 price target, implying substantial upside from recent trading levels. MarketBeat Kyverna Therapeutics analyst estimates
• Positive Sentiment: The revised forecasts also improved expected quarterly results for Q3 and Q4 2026 and Q1 through Q4 2027, suggesting HC Wainwright sees a better earnings trajectory, although KYTX is still expected to remain unprofitable. The company recently beat quarterly EPS expectations, reporting a $0.63 loss versus the $0.68 consensus loss.
• Positive Sentiment: Kyverna’s reported progress toward potential approval supports the long-term investment case because successful regulatory advancement could improve the prospects for its cell-therapy platform. Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
• Neutral Sentiment: Despite the favorable HC Wainwright view, broader analyst opinions on KYTX remain mixed. That lack of consensus likely limited the stock’s reaction to the improved estimates and approval-related progress. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Kyverna remains a development-stage biotechnology company with substantial expected losses, making the stock highly dependent on clinical, regulatory and financing progress. Its beta of 1.93 also indicates elevated volatility.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. JPMorgan Chase & Co. decreased their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 13th. Wall Street Zen downgraded shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Finally, HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kyverna Therapeutics has an average rating of "Moderate Buy" and an average price target of $30.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source